Elanco Animal Health Incorporated (ELAN, Financial) experienced a significant stock drop of 5.09%, trading at $13.24 per share with a volume of 5.56185 million shares. The stock's turnover rate was 1.13%, with a price fluctuation of 4.95%.
In its recent financial report, Elanco recorded revenue of $1.184 billion and a net loss of $50 million, equating to an earnings per share of -$0.10. The company's gross profit stood at $558 million, with a P/E ratio of -5.20.
Of the 14 institutions rating the stock, 64% recommend buying, while 36% suggest holding, and none advise selling. The pharmaceutical sector, where Elanco belongs, saw an overall decline of 0.10%.
Other stocks in the industry showed varied performances: Sunshine Biopharma Inc, Painreform Ltd., and Scilex Holding Company posted significant gains. Active stocks included Nature's Sunshine Products, Painreform Ltd., and Suzhou Xuantang with turnover rates of 132.97%, 79.13%, and 20.60%, respectively. Stocks like Nature's Sunshine Products and Sunshine Biopharma Inc exhibited high price volatility.
Elanco Animal Health Inc is focused on innovating, developing, manufacturing, and selling products for both companion and consumable animals across more than 90 countries, with a portfolio of approximately 200 brands.
